UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response:
0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
1. Name and Address of Reporting Person*PFIZER INC
(Last)
(First)
(Middle)
235 E. 42ND STREET
(Street)
NEW YORK
NY
10017
(City)
(State)
(Zip)
2. Issuer Name and Ticker or Trading Symbol
Celladon Corp
[ CLDN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director
10% Owner
Officer (give title below)
Other (specify below)
3. Date of Earliest Transaction
(Month/Day/Year)
02/04/2014
4. If Amendment, Date of Original Filed
(Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
3)
2. Transaction Date
(Month/Day/Year)
2A. Deemed Execution Date, if any
(Month/Day/Year)
3. Transaction Code (Instr.
8)
4. Securities Acquired (A) or Disposed Of (D) (Instr.
3, 4 and 5)
5.
Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
7. Nature of Indirect Beneficial Ownership (Instr.
4)
Code
Amount
(A) or (D)
Price
Common Stock
02/04/2014
1,544,397
(1)
1,544,397
Common Stock
02/04/2014
23,145(2)
$8
1,567,542
Common Stock
02/04/2014
227,261(3)
$8
1,794,803
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
3)
2. Conversion or Exercise Price of Derivative Security
3. Transaction Date
(Month/Day/Year)
3A. Deemed Execution Date, if any
(Month/Day/Year)
4. Transaction Code (Instr.
8)
5.
Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
3, 4 and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Securities Underlying Derivative Security (Instr.
3 and 4)
8. Price of Derivative Security (Instr.
5)
9.
Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
4)
10. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
11. Nature of Indirect Beneficial Ownership (Instr.
4)
Code
(A)
(D)
Date Exercisable
Expiration Date
Title
Amount or Number of Shares
Series A-1 Convertible Preferred Stock
(1)
02/04/2014
19,289,531(1)
(1)
(1)
Common Stock
1,544,397
$0.00
Convertible Promissory Notes
$8(2)
02/04/2014
23,145
(2)
(2)
Common Stock
23,145
$8
Series A-1 Preferred Warrants
$0.449
02/04/2014
C(4)
532,818
10/15/2013
10/15/2018
Series A-1 Preferred Stock
532,818
$0.00
Common Warrants
$5.61
02/04/2014
C(4)
42,659
10/15/2013
10/15/2018
Common Stock
42,659
$0.00
42,659
Explanation of Responses:
1. Every 12.49 shares of Series A-1 Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
2. Automatic conversion, in connection with the Issuer's initial public offering, of convertible promissory notes, including principal and accrued interest.
3. The shares were purchased at the Issuer's initial public offering.
4. Represents the automatic conversion of Series A-1 Preferred Warrants into Common Stock Warrants on a 1-for-12.49 basis upon the closing of the Issuer's initial public offering.
Remarks:
/s/ Susan Grant, Assistant Secretary on behalf of Pfizer Inc.
02/06/2014
** Signature of Reporting Person
Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person,
see
Instruction
(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.